Carbidopa Monohydrate
|
|
- CAS-Nr.
- 38821-49-7
- Englisch Name:
- Carbidopa Monohydrate
- Synonyma:
- lodosyn;CARBIDOPA;Carbidopa RS;CARBIDOPA,USP;Carbidopa CRS;CARBIDOPA HYDRATE;Carbidopa (400 mg);Carbidopa(CEP/FDA);Carbidopa Capsules;CARBIDOPA 1-HYDRATE
- CBNumber:
- CB7445183
- Summenformel:
- C10H16N2O5
- Molgewicht:
- 244.25
- MOL-Datei:
- 38821-49-7.mol
|
Carbidopa Monohydrate Eigenschaften
- storage temp.
- Keep in dark place,Inert atmosphere,Room temperature
- L?slichkeit
- Slightly soluble in water, very slightly soluble in ethanol (96 per cent), practically insoluble in methylene chloride. It dissolves in dilute solutions of mineral acids.
- Aggregatzustand
- Solid
- Farbe
- White to Off-White
- CAS Datenbank
- 38821-49-7(CAS DataBase Reference)
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
WGK Germany |
3 |
|
|
RTECS-Nr. |
MW5300000 |
|
|
HazardClass |
IRRITANT |
|
|
HS Code |
2928002500 |
|
|
Toxizit?t |
mouse,LD50,intraperitoneal,148mg/kg (148mg/kg),SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYEBEHAVIORAL: ATAXIABEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY),Toxicology and Applied Pharmacology. Vol. 29, Pg. 181, 1974. |
|
|
Bildanzeige (GHS) |
|
Alarmwort |
Warnung |
Gefahrenhinweise |
Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
|
Sicherheit |
P264 |
Nach Gebrauch gründlich waschen. |
P264 |
Nach Gebrauch gründlich waschen. |
P270 |
Bei Gebrauch nicht essen, trinken oder rauchen. |
P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
P301+P312 |
BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen. |
P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
P337+P313 |
Bei anhaltender Augenreizung: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen. |
|
Carbidopa Monohydrate Chemische Eigenschaften,Einsatz,Produktion Methoden
Chemische Eigenschaften
white or yellowish-white powder. almost odorless. combined with levodopa for Parkinson's disease and Parkinson's syndrome.
Verwenden
Carbidopa ((S)-(-)-Carbidopa) monohydrate, a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa monohydrate is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa monohydrate inhibits pancreatic cancer cell and tumor growth.
Definition
ChEBI: Carbidopa is the hydrate of 3-(3,4-dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa. It has a role as an EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor, an antiparkinson drug, a dopaminergic agent and an antidyskinesia agent. It is a member of hydrazines, a hydrate, a monocarboxylic acid and a member of catechols. It contains a carbidopa (anhydrous).
Allgemeine Beschreibung
Carbidopa, (S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid, is a whitecrystalline powder, slightly soluble in water (pK
a=7.8).Carbidopa is absorbed slower than levodopa and is 36%plasma protein bound.Carbidopa is metabolized to twomain metabolites (α-methyl-3-methoxy-4-hydroxyphenylpropionicacid and α-methyl-3,4-dihydroxyphenylpropionicacid). These two metabolites are primarily eliminated in theurine unchanged or as glucuronide conjugates. Unchangedcarbidopa accounts for 30% of the total urinary excretion.No drug interactions have been described.
Carbidopa Monohydrate Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Carbidopa Monohydrate Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 339)Lieferanten
38821-49-7()Verwandte Suche:
- (S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropionic Acid
- Carbidopa SynonyMs (+)-2-(3,4-Dihydroxybenzyl)-2-hydrazinopropionic acid Monohydrate
- (S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropionic acid monohydrate
- Carbidopa for system suitability
- CARBIDOPA
- CARBIDOPA HYDRATE
- CARBIDOPA MONOHYDRATE
- (S)-(-)-CARBIDOPA MONOHYDRATE
- CARBIDOPA 1-HYDRATE
- CARBIDOPA 1-HYDRATE, PHARMA
- CARBIDOPA,USP
- CARBIDOPA(GMP CERTIFICATE)
- (+)-2-(3,4-Dihydroxybenzyl)-2-hydrazinopropionic acid monohydrate
- Carbidopa (400 mg)
- (-)-l-alpha-hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamicacidmonohydrat
- (-)-l-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-hydrocinnamicacimonohydr
- alpha-hydrazino-3,4-dihydroxy-alpha-methyl-benzenepropanoicacimonohydra
- lodosyn
- Carbidopa(CEP/FDA)
- 3-(4-(3-Butyl-3-methyltriaz-1-en-1-yl)phenyl)propanehydrazide
- Carbidopa CRS
- Carbidopa Monohydrate>
- Carbidopa for system suitability CRS
- Carbidopa RS
- (S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate
- Carbidopa Monohydrate USP/EP/BP
- Carbidopa for system suitability (Y0001713)
- Carbidopa (1095506)
- Carbidopa Capsules
- Carbidopa monohydrate, 10 mM in DMSO
- 38821-49-7
- 38812-49-7
- 156-2-26
- C10H14N2O4H2O
- Inhibitors
- Pharmaceutical intermediates
- Other APIs